FDA approves t:slim X2 pump with Dexcom G5 mobile CGM

The FDA has approved the t:slim X2 Insulin Pump with Dexcom G5 Mobile continuous glucose monitoring integration, according to a press release from manufacturer Tandem Diabetes Care. The device will allow people with diabetes make treatment decisions without a finger prick, according to the release.

“We are setting a new standard in our industry by simultaneously offering our existing and future customers the benefits of best-in-class CGM integration on our simple-to-use touchscreen insulin pump,” Kim Blickenstaff, president and CEO of Tandem Diabetes Care, said in the release. “The t:slim X2 Pump is designed to accelerate the pace in which we can bring new innovations to people with diabetes, which is of particular importance as we develop software updates to add automated insulin delivery algorithms to our platform.”

Current t:slim X2 Pump users will have no-cost access via remote software update to the new options featured on the pump. People who currently use the pump can expect an email message with instructions on how to perform the updates. The pump is currently approved for people aged 6 years and older.

“Dexcom has been moving its technology forward at a rapid pace, and Tandem’s ability to roll out remote software updates like this opens up exciting possibilities for faster integrations of our future products,” Steve Pacelli, executive vice president of strategy and corporate development at Dexcom, said in the release. “We are excited to have our latest CGM technology integrated with their t:slim X2 insulin Pump and to see it offered not only to new customers, but also to existing t:slim X2 Pump users.”